Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis Patients
Status:
Terminated
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
In maintenance hemodialysis patients, regular administration of parenteral iron by addition
of soluble ferric pyrophosphate (SFP) to the dialysate, when compared to conventional
dialysate, is effective in preventing the development of iron deficiency, thereby maintaining
hemoglobin level; is clinically safe and does not lead to oxidative stress or inflammation.
Phase:
N/A
Details
Lead Sponsor:
Charles Drew University of Medicine and Science
Collaborators:
National Institutes of Health (NIH) Rockwell Medical Technologies, Inc.